Kalsiumantagonister ved høyt blodtrykk

Tidsskrift for den Norske Laegeforening

Volumn 129, Issue 23, 2009, Pages 2488-2489

  Landmark, Knud ^a   Reikvam, Åsmund ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; HYPERTENSION; REVIEW; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; HYPERTENSION; TREATMENT OUTCOME;

EID: 73949146949     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.09.0299     Document Type: Article

References (11)

1. Blood Pressure Lowering Treatment Trialist's Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-3.
2. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressurelowering regimens on major cardiovascular events: results of propectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
3. Pahor M, Psaty BM, Alderman MH et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356: 1949-54.
4. Psaty BM, Lumley T, Furberg CD et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. A network meta-analysis. JAMA 2003; 289: 2534-44.
5. www.kunnskapssenteret.no/Publikasjoner/4786.cms (15.10.2009).
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981-97.
7. Dahlöf B, Sever PS, Poulter NR et al, for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
8. Poulter NR, Wedel H, Dahlöf B et al, for the ASCOT investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-13.
9. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. N Engl J Med 2008; 359: 2417-28.
10. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.
11. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-72.